Happy #IndependenceDay! We wish our PureTech community a happy and safe Fourth of July celebration.
About us
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
- Website
-
http://www.puretechhealth.com
External link for PureTech Health
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
Locations
-
Primary
Get directions
6 Tide St
Boston, Massachusetts 02210, US
Employees at PureTech Health
Updates
-
We are delighted to share that Raju Kucherlapati, PhD, distinguished Professor of Medicine at Harvard Medical School, has been appointed permanent Chair of the PureTech Board of Directors. https://bit.ly/45zq5wj
-
-
Today we honor #Juneteenth, a day of profound significance in US history. Earlier this month, we had the privilege of hosting local historian Sean Osborne, PE who highlighted for us the bravery of #QuockWalker (among other heroes) and how his courage led to MA being one of the first states to abolish slavery.
-
-
PureTech Health reposted this
We are pleased to welcome Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D. as General Counsel at Seaport. A CNS drug development expert, Dr. Loebel was the former Chief Executive Officer and Chief Medical Officer at Sunovion Pharmaceuticals. An experienced attorney, Lana brings over two decades of legal expertise, including corporate governance, navigating M&A transactions, licensing and partnerships, and intellectual property matters. Commenting on the appointments, Daphne Zohar, Founder and CEO of Seaport said: “I’m delighted to welcome two more outstanding members to our senior executive team. As we design and run studies to advance our clinical-stage pipeline of novel therapeutics focused on important mental health conditions, Tony’s deep understanding of neuropsychiatric drug development builds on our team’s distinct advantages. We are rapidly growing our company and Lana’s experience across all facets of legal, including corporate governance, transactions, and IP, will be an important resource to Seaport. I’m thrilled to have both Tony and Lana onboard.” https://lnkd.in/exdWvKai
-
-
Our CEO, Bharatt Chowrira, Ph.D., J.D., & Co-founder and President, Eric Elenko Elenko, Ph.D., participated in a fireside chat at the Jefferies Global Healthcare Conference, where they discussed our robust R&D engine. Listen here: https://bit.ly/4c4m6Kb #JefferiesHealthcare
-
-
Our Chief Executive Officer, Bharatt Chowrira, and Co-founder & President, Eric Elenko, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th, 2024, at 10:00am EDT / 3:00pm BST https://bit.ly/3KfaPuG
-
-
Thank you American Thoracic Society for an incredible #ATS2024. Our team had many insightful interactions, especially at our presentation of the adverse event burden with current treatments for #IPF. We hope to make a difference for patients with idiopathic pulmonary fibrosis, and we look forward to sharing data from our Phase 2b trial of LYT-100 in Q4.
-
-
Congratulations to our Founded Entity Vedanta Biosciences, Inc. on the initiation of the global Phase 3 trial of VE303 for the prevention of recurrent #Cdiff. https://bit.ly/4btIrks
-
-
Additional data from the Phase 1 and Phase 2a trials of SPT-300 will be highlighted at #SOBP2024, underscoring the potential for our Founded Entity Seaport Therapeutics's planned development in #mooddisorders and #anxietydisorders, including #anxiousdepression https://bit.ly/3Uy3IlU
Our Co-founder and Chief Scientific Officer Michael C. Chen will present data from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting (#SOBP2024). The data summarizes some of the evidence supporting the core mechanisms of SPT-300 and support our planned studies in mood and #anxiety disorders, including anxious #depression https://bit.ly/3JReH4Q
-
-
Today our newest Founded Entity Seaport Therapeutics announced key additions to its board and Executive Team https://bit.ly/4acvDxx
We're pleased to welcome Denice Torres, JD (previously Karuna, J&J, Lilly) to our Board & announce the executive appointments of Eric Green, MBA (previously Alnylam) as Chief Operating Officer and Co-founder Michael C. Chen, PhD, (previously PureTech) as Chief Scientific Officer.